Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States.

Authors

Matthew Braithwaite

University of Utah, Salt Lake City, UT

Matthew Braithwaite , Christopher Duane Nevala-Plagemann , Kelsey Baron , Benjamin Haaland , Lisa M. Pappas , Ignacio Garrido-Laguna

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4030)

DOI

10.1200/JCO.2020.38.15_suppl.4030

Abstract #

4030

Poster Bd #

Abstract Disclosures

FEATURED

Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States.

Authors

Matthew Braithwaite

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases: The randomized phase III CAIRO5 study of the Dutch Colorectal Cancer Group.

Poster

Effect of p16 immunohistochemical expression (exp) on irinotecan in metastatic colorectal cancer (mCRC): A translational analysis of the TRIBE and TRIBE2 studies.

Poster

FOLFOXIRI ± molecular targeting agent (bevacizumab or panitumumab) for conversion from unresectable to resectable in the advanced/recurrent colorectal cancer.

Poster

Optimal molecular-targeted therapies as first-line treatment for RAS wild-type, right-sided metastatic colorectal cancer from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.